July 27, 2016
Recommended Topic Related To:

Methyldopate Hcl

"The U.S. Department of Health and Human Services today launched an annual challenge designed to identify and honor clinicians and health care teams that have helped their patients control high blood pressure and prevent heart attacks and strokes."...


Methyldopate Hcl



Acute overdosage may produce acute hypotension with other responses attributable to brain and gastrointestinal malfunction (excessive sedation, weakness, bradycardia, dizziness, lightheadedness, constipation, distention, flatus, diarrhea, nausea, vomiting).

In the event of overdosage, symptomatic and supportive measures should be employed. Management includes special attention to cardiac rate and output, blood volume, electrolyte balance, paralytic ileus, urinary function and cerebral activity.

Sympathomimetic drugs [e.g., levarterenol, epinephrine, ARAMINE* (Metaraminol Bitartrate, MSD)] may be indicated.

The acute intravenous LD50 of Methyldopate HCl (methyldopate hydrochloride injection, solution) in the mouse is 321 mg/kg.


Methyldopate hydrochloride is contraindicated in patients:

-with active hepatic disease, such as acute hepatitis and active cirrhosis.
-with liver disorders previously associated with methyldopa therapy (see WARNINGS).
-with hypersensitivity to any component of this product, including sulfites (see WARNINGS).
-on therapy with monoamine oxidase (MAO) inhibitors.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 8/11/2008


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get tips on handling your hypertension.